Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders
01 déc. 2021 08h30 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit
26 oct. 2021 08h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program
25 oct. 2021 08h30 HE
|
Akari Therapeutics Plc
Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in a model of allergic eye diseaseBuilding on early clinical data in atopic...
Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
22 sept. 2021 09h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress
22 sept. 2021 08h30 HE
|
Akari Therapeutics Plc
Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP).Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic...
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium
10 sept. 2021 08h30 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference
07 sept. 2021 07h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces Private Placement
07 juil. 2021 09h15 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to...
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
29 juin 2021 16h01 HE
|
Akari Therapeutics Plc
Open Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP) Phase III study of nomacopan in severe...
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid
28 avr. 2021 08h00 HE
|
Akari Therapeutics Plc
A multicenter Phase III study of nomacopan for the treatment of moderate and severe bullous pemphigoid (BP) has been initiatedNomacopan has potential to replace long term steroid treatment (standard...